Binaprofen (Felbinac Tromethamol Injection)

Pain / Inflammation

First program; novel injectable formulation overcoming the poor solubility common to NSAIDs (e.g., the ibuprofen injection recall caused by insoluble particles)

Approved (Jan 2026)

Exclusively licensed to Shijiazhuang Yiling Pharmaceutical; RMB 48M fully received

XY03-EA

Ischemic Stroke

Butylphthalide derivative; improves oral bioavailability from ~6% to 30% and enhances brain-tissue targeting

Phase III ongoing (positive Phase II)

Licensed to Yiling; RMB 18M upfront + RMB 20M milestones

DG68 (ZONK2002)

Stroke

FIC multi-target; oral dosing with significant efficacy advantage over injectable edaravone

IND submitted

Co-development with Guangzhou Daguang Pharma; upfront payment + 30% equity

ZONK1901

Prostate Cancer

FIC multi-target anti-resistance; unexpected breakthrough addressing inevitable drug resistance; superior efficacy vs. enzalutamide and abiraterone

PCC

Available for partnership

ZONK2301

Liver & Lung Fibrosis

FIC multi-target; novel non-pirfenidone scaffold; superior anti-fibrotic efficacy vs. pirfenidone, more pronounced in liver fibrosis

PCC; undergoing further optimization to address remaining development issues

Available for partnership (subject to ongoing optimization)

Ferroptosis Inhibitor Program

To be disclosed

Innovative early-stage research

Early research

Not yet available